25 XP   0   0   10

Revance The
Buy, Hold or Sell?

Let's analyse Revance together

PenkeI guess you are interested in Revance The. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Revance The. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Revance The

I send you an email if I find something interesting about Revance The.

Quick analysis of Revance (30 sec.)










What can you expect buying and holding a share of Revance? (30 sec.)

How much money do you get?

How much money do you get?
$0.08
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$-1.45
Expected worth in 1 year
$-3.03
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-1.49
Return On Investment
-45.4%

For what price can you sell your share?

Current Price per Share
$3.29
Expected price per share
$0 - $7.56
How sure are you?
50%

1. Valuation of Revance (5 min.)




Live pricePrice per Share (EOD)

$3.29

Intrinsic Value Per Share

$-20.20 - $-0.62

Total Value Per Share

$-21.65 - $-2.07

2. Growth of Revance (5 min.)




Is Revance growing?

Current yearPrevious yearGrowGrow %
How rich?-$151.6m$45.3m-$109.7m-170.3%

How much money is Revance making?

Current yearPrevious yearGrowGrow %
Making money-$82.5m-$88.7m$6.2m7.5%
Net Profit Margin-144.5%-263.3%--

How much money comes from the company's main activities?

3. Financial Health of Revance (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#999 / 1010

Most Revenue
#139 / 1010

Most Profit
#953 / 1010

Most Efficient
#597 / 1010

What can you expect buying and holding a share of Revance? (5 min.)

Welcome investor! Revance's management wants to use your money to grow the business. In return you get a share of Revance.

What can you expect buying and holding a share of Revance?

First you should know what it really means to hold a share of Revance. And how you can make/lose money.

Speculation

The Price per Share of Revance is $3.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Revance.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Revance, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.45. Based on the TTM, the Book Value Change Per Share is $-0.39 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.02 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Revance.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.53-16.2%-0.78-23.6%-0.86-26.0%-0.67-20.5%-0.45-13.8%
Usd Book Value Change Per Share-0.44-13.2%-0.39-12.0%-0.13-4.1%-0.14-4.3%0.000.0%
Usd Dividend Per Share0.000.0%0.020.6%0.010.3%0.010.2%0.000.1%
Usd Total Gains Per Share-0.44-13.2%-0.37-11.3%-0.13-3.8%-0.14-4.2%0.000.1%
Usd Price Per Share8.79-19.45-19.70-20.45-22.73-
Price to Earnings Ratio-4.11--7.51--6.34--8.26--18.87-
Price-to-Total Gains Ratio-20.18--18.77--23.60-84.63-22.21-
Price to Book Ratio-6.04--11.17--73.96--10.10-2.59-
Price-to-Total Gains Ratio-20.18--18.77--23.60-84.63-22.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.29
Number of shares303
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.01
Usd Book Value Change Per Share-0.39-0.14
Usd Total Gains Per Share-0.37-0.14
Gains per Quarter (303 shares)-113.08-41.41
Gains per Year (303 shares)-452.30-165.64
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
125-477-4627-173-176
250-955-91414-346-342
375-1432-136622-518-508
4100-1910-181829-691-674
5126-2387-227036-864-840
6151-2864-272243-1037-1006
7176-3342-317450-1210-1172
8201-3819-362658-1383-1338
9226-4297-407865-1555-1504
10251-4774-453072-1728-1670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.045.01.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%7.013.00.035.0%12.028.00.030.0%13.031.02.028.3%
Dividend per Share3.00.01.075.0%5.00.07.041.7%5.00.015.025.0%5.00.035.012.5%5.00.041.010.9%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%7.013.00.035.0%12.028.00.030.0%13.031.02.028.3%

Fundamentals of Revance

About Revance The

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Fundamental data was last updated by Penke on 2024-04-12 17:36:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Revance The.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Revance earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Revance to the Biotechnology industry mean.
  • A Net Profit Margin of -79.8% means that $-0.80 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Revance The:

  • The MRQ is -79.8%. The company is making a huge loss. -2
  • The TTM is -144.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-79.8%TTM-144.5%+64.7%
TTM-144.5%YOY-263.3%+118.7%
TTM-144.5%5Y-14,334.4%+14,189.9%
5Y-14,334.4%10Y-20,384.2%+6,049.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-79.8%-207.2%+127.4%
TTM-144.5%-216.8%+72.3%
YOY-263.3%-282.3%+19.0%
5Y-14,334.4%-436.8%-13,897.6%
10Y-20,384.2%-597.3%-19,786.9%
1.1.2. Return on Assets

Shows how efficient Revance is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Revance to the Biotechnology industry mean.
  • -11.6% Return on Assets means that Revance generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Revance The:

  • The MRQ is -11.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.6%TTM-15.4%+3.7%
TTM-15.4%YOY-14.4%-0.9%
TTM-15.4%5Y-13.1%-2.3%
5Y-13.1%10Y-12.3%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.6%-13.3%+1.7%
TTM-15.4%-12.8%-2.6%
YOY-14.4%-11.6%-2.8%
5Y-13.1%-13.8%+0.7%
10Y-12.3%-15.6%+3.3%
1.1.3. Return on Equity

Shows how efficient Revance is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Revance to the Biotechnology industry mean.
  • 0.0% Return on Equity means Revance generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Revance The:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-62.8%+62.8%
TTM-62.8%YOY-364.4%+301.5%
TTM-62.8%5Y-105.0%+42.2%
5Y-105.0%10Y-59.5%-45.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM-62.8%-16.1%-46.7%
YOY-364.4%-14.9%-349.5%
5Y-105.0%-19.3%-85.7%
10Y-59.5%-20.1%-39.4%

1.2. Operating Efficiency of Revance The.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Revance is operating .

  • Measures how much profit Revance makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Revance to the Biotechnology industry mean.
  • An Operating Margin of -76.1% means the company generated $-0.76  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Revance The:

  • The MRQ is -76.1%. The company is operating very inefficient. -2
  • The TTM is -93.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-76.1%TTM-93.9%+17.9%
TTM-93.9%YOY-216.7%+122.7%
TTM-93.9%5Y-14,063.2%+13,969.3%
5Y-14,063.2%10Y-19,560.8%+5,497.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-76.1%-298.0%+221.9%
TTM-93.9%-238.5%+144.6%
YOY-216.7%-288.4%+71.7%
5Y-14,063.2%-486.2%-13,577.0%
10Y-19,560.8%-628.4%-18,932.4%
1.2.2. Operating Ratio

Measures how efficient Revance is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.76 means that the operating costs are $1.76 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Revance The:

  • The MRQ is 1.761. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.966. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.761TTM1.966-0.205
TTM1.966YOY3.167-1.201
TTM1.9665Y144.551-142.586
5Y144.55110Y317.106-172.555
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7613.235-1.474
TTM1.9663.310-1.344
YOY3.1673.838-0.671
5Y144.5515.679+138.872
10Y317.1067.823+309.283

1.3. Liquidity of Revance The.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Revance is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.80 means the company has $3.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Revance The:

  • The MRQ is 3.798. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.446. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.798TTM4.446-0.648
TTM4.446YOY4.477-0.031
TTM4.4465Y6.135-1.689
5Y6.13510Y9.215-3.080
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7983.863-0.065
TTM4.4464.169+0.277
YOY4.4775.337-0.860
5Y6.1356.122+0.013
10Y9.2156.434+2.781
1.3.2. Quick Ratio

Measures if Revance is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Revance to the Biotechnology industry mean.
  • A Quick Ratio of 4.47 means the company can pay off $4.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Revance The:

  • The MRQ is 4.469. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.583. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.469TTM5.583-1.114
TTM5.583YOY6.624-1.041
TTM5.5835Y8.542-2.959
5Y8.54210Y12.619-4.077
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4693.504+0.965
TTM5.5833.991+1.592
YOY6.6245.371+1.253
5Y8.5426.088+2.454
10Y12.6196.395+6.224

1.4. Solvency of Revance The.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Revance assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Revance to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.32 means that Revance assets are financed with 131.7% credit (debt) and the remaining percentage (100% - 131.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Revance The:

  • The MRQ is 1.317. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.130. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.317TTM1.130+0.187
TTM1.130YOY0.935+0.195
TTM1.1305Y0.736+0.394
5Y0.73610Y0.440+0.296
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3170.339+0.978
TTM1.1300.337+0.793
YOY0.9350.271+0.664
5Y0.7360.368+0.368
10Y0.4400.388+0.052
1.4.2. Debt to Equity Ratio

Measures if Revance is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Revance to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Revance The:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM5.327-5.327
TTM5.327YOY18.277-12.950
TTM5.3275Y5.777-0.450
5Y5.77710Y2.977+2.800
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.392-0.392
TTM5.3270.403+4.924
YOY18.2770.335+17.942
5Y5.7770.427+5.350
10Y2.9770.461+2.516

2. Market Valuation of Revance The

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Revance generates.

  • Above 15 is considered overpriced but always compare Revance to the Biotechnology industry mean.
  • A PE ratio of -4.11 means the investor is paying $-4.11 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Revance The:

  • The EOD is -1.539. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.112. Based on the earnings, the company is expensive. -2
  • The TTM is -7.515. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.539MRQ-4.112+2.573
MRQ-4.112TTM-7.515+3.403
TTM-7.515YOY-6.340-1.175
TTM-7.5155Y-8.259+0.744
5Y-8.25910Y-18.871+10.612
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.539-2.300+0.761
MRQ-4.112-2.656-1.456
TTM-7.515-2.718-4.797
YOY-6.340-4.145-2.195
5Y-8.259-6.258-2.001
10Y-18.871-6.315-12.556
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Revance The:

  • The EOD is -1.926. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.145. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.718. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.926MRQ-5.145+3.219
MRQ-5.145TTM-8.718+3.573
TTM-8.718YOY-9.005+0.286
TTM-8.7185Y-12.508+3.789
5Y-12.50810Y-24.656+12.149
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.926-2.974+1.048
MRQ-5.145-3.306-1.839
TTM-8.718-3.508-5.210
YOY-9.005-5.613-3.392
5Y-12.508-8.378-4.130
10Y-24.656-8.873-15.783
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Revance is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -6.04 means the investor is paying $-6.04 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Revance The:

  • The EOD is -2.262. Based on the equity, the company is expensive. -2
  • The MRQ is -6.042. Based on the equity, the company is expensive. -2
  • The TTM is -11.169. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.262MRQ-6.042+3.781
MRQ-6.042TTM-11.169+5.126
TTM-11.169YOY-73.965+62.796
TTM-11.1695Y-10.105-1.064
5Y-10.10510Y2.595-12.700
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.2621.914-4.176
MRQ-6.0422.116-8.158
TTM-11.1692.097-13.266
YOY-73.9652.881-76.846
5Y-10.1053.550-13.655
10Y2.5953.936-1.341
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Revance The.

3.1. Institutions holding Revance The

Institutions are holding 75.996% of the shares of Revance The.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Capital World Investors11.45610.018711939076-21744-0.1818
2023-12-31BlackRock Inc7.15190.0017745337169665110.3105
2023-12-31Palo Alto Investors, LLC5.02544.1477523728486750.1659
2023-12-31Vanguard Group Inc4.86460.00150696252781665.8055
2023-12-31Franklin Resources Inc4.55740.0195474953971197817.6339
2023-12-31JPMorgan Chase & Co4.45560.00394643419132220.2856
2023-12-31Polar Capital Holdings PLC3.0410.17073169239-991072-23.8221
2023-12-31State Street Corporation2.41970.001125216931885858.083
2023-12-31Geode Capital Management, LLC1.84660.001819244211441448.0967
2023-12-31Amvescap Plc.1.53780.00341602622-1299818-44.7836
2023-12-31Goldman Sachs Group Inc1.50390.0012156725642261236.9208
2023-12-31Rubric Capital Management LP1.40240.26661461474-138526-8.6579
2023-09-30Point72 Asset Management, L.P.1.3080.04561363168686735101.523
2023-12-31CIBC Global Asset Management Inc1.10090.03771147294820587251.1691
2023-12-31Jennison Associates LLC0.99060.00681032352347363.4819
2023-12-31BAMCO Inc0.98230.024102366334290.3361
2023-12-31Walleye Trading Advisors, LLC0.89030.0173927814622022203.4134
2023-12-31Northern Trust Corp0.85160.0014887536491805.8662
2023-12-31Morgan Stanley - Brokerage Accounts0.84370.000787924927705446.0074
2023-09-30Deerfield Management Co0.83480.219987000000
Total 57.06464.990759470095+2506616+4.2%

3.2. Funds holding Revance The

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31American Funds SMALLCAP World A6.45810.0822673035700
2023-12-31Capital Group New Economy Comp4.82850.1438503200055322112.352
2023-12-31American Funds New Economy A4.82850.1438503200055322112.352
2024-02-29Polar Capital Healthcare Opports Inc2.65521.1728276713900
2024-02-29Vanguard Total Stock Mkt Idx Inv2.3810.00112481369-246000-9.0197
2024-03-28iShares Russell 2000 ETF2.04570.016213193510290.0483
2024-02-29Franklin Biotechnology Discv A(acc)USD1.96240.7912204515300
2024-02-29JPMorgan Small Cap Growth A1.51220.27791575902-1889-0.1197
2023-12-31Franklin US Small Cap Growth Equity1.47430.4872153649234640029.107
2024-02-29Franklin Small Cap Growth Adv1.47430.3783153649200
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.28770.00941342034-1769-0.1316
2023-12-31Renaissance Global Health Care1.09871.8971114498500
2024-02-29Franklin Biotechnology Discovery A0.90550.700594366000
2024-01-31Fidelity Small Cap Index0.85220.018888122165061.8937
2023-12-31Baron Discovery Strategy0.74440.477577583200
2023-12-31Baron Discovery Institutional0.74440.477277583200
2024-03-28iShares Russell 2000 Growth ETF0.73030.0321761059-885-0.1162
2023-12-31Invesco Small Cap Core0.71810.3868748386298764.158
2024-03-28iShares Biotechnology ETF0.67890.045670748310462017.3539
2024-02-29Fidelity Extended Market Index0.5490.01075721738176416.6726
Total 37.92947.549239528405+1436094+3.6%

3.3. Insider Transactions

Insiders are holding 8.475% of the shares of Revance The.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-18Dustin S SjutsSELL92115.04
2024-03-18Dwight MoxieSELL81255.04
2024-03-18Tobin SchilkeSELL93615.04
2023-09-05Dwight MoxieSELL2385317.81
2023-08-03Mark J FoleySELL2627922.57
2023-07-03Mark J FoleySELL2627924.94
2023-07-03Tobin SchilkeSELL170125.04
2023-06-15Carey Oconnor KolajaSELL250028.24
2023-06-09Dustin S SjutsSELL500030.82
2023-06-09Mark J FoleySELL3127930.72
2023-06-01Tobin SchilkeSELL270130.57
2023-05-15Dustin S SjutsSELL2101534.55
2023-05-15Dwight MoxieSELL2140134.55
2023-05-15Mark J FoleySELL7044734.55
2023-05-01Tobin SchilkeSELL320131.7

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Revance The compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.436-0.394-10%-0.134-69%-0.143-67%0.001-30649%
Book Value Per Share---1.455-0.618-58%0.435-435%1.267-215%1.522-196%
Current Ratio--3.7984.446-15%4.477-15%6.135-38%9.215-59%
Debt To Asset Ratio--1.3171.130+17%0.935+41%0.736+79%0.440+199%
Debt To Equity Ratio---5.327-100%18.277-100%5.777-100%2.977-100%
Dividend Per Share---0.021-100%0.009-100%0.006-100%0.003-100%
Eps---0.534-0.777+45%-0.855+60%-0.673+26%-0.454-15%
Free Cash Flow Per Share---0.427-0.536+26%-0.545+28%-0.471+10%-0.330-23%
Free Cash Flow To Equity Per Share---0.443-0.208-53%0.250-277%0.033-1443%0.058-863%
Gross Profit Margin--5.5502.149+158%1.044+432%1.374+304%1.187+368%
Intrinsic Value_10Y_max---0.615--------
Intrinsic Value_10Y_min---20.198--------
Intrinsic Value_1Y_max---1.140--------
Intrinsic Value_1Y_min---2.191--------
Intrinsic Value_3Y_max---2.603--------
Intrinsic Value_3Y_min---6.478--------
Intrinsic Value_5Y_max---3.076--------
Intrinsic Value_5Y_min---10.615--------
Market Cap342870640.000-167%916058640.0002026480120.000-55%2052534120.000-55%2131165092.000-57%2368543086.000-61%
Net Profit Margin---0.798-1.445+81%-2.633+230%-143.344+17863%-203.842+25444%
Operating Margin---0.761-0.939+23%-2.167+185%-140.632+18383%-195.608+25608%
Operating Ratio--1.7611.966-10%3.167-44%144.551-99%317.106-99%
Pb Ratio-2.262+63%-6.042-11.169+85%-73.965+1124%-10.105+67%2.595-333%
Pe Ratio-1.539+63%-4.112-7.515+83%-6.340+54%-8.259+101%-18.871+359%
Price Per Share3.290-167%8.79019.445-55%19.695-55%20.450-57%22.727-61%
Price To Free Cash Flow Ratio-1.926+63%-5.145-8.718+69%-9.005+75%-12.508+143%-24.656+379%
Price To Total Gains Ratio-7.552+63%-20.176-18.771-7%-23.597+17%84.634-124%22.215-191%
Quick Ratio--4.4695.583-20%6.624-33%8.542-48%12.619-65%
Return On Assets---0.116-0.154+32%-0.144+24%-0.131+12%-0.123+6%
Return On Equity----0.6280%-3.6440%-1.0500%-0.5950%
Total Gains Per Share---0.436-0.373-14%-0.125-71%-0.137-69%0.004-10015%
Usd Book Value---151604000.000-64423000.000-58%45305750.000-435%132014900.000-215%158582475.000-196%
Usd Book Value Change Per Share---0.436-0.394-10%-0.134-69%-0.143-67%0.001-30649%
Usd Book Value Per Share---1.455-0.618-58%0.435-435%1.267-215%1.522-196%
Usd Dividend Per Share---0.021-100%0.009-100%0.006-100%0.003-100%
Usd Eps---0.534-0.777+45%-0.855+60%-0.673+26%-0.454-15%
Usd Free Cash Flow---44510000.000-55865250.000+26%-56844500.000+28%-49128450.000+10%-34405375.000-23%
Usd Free Cash Flow Per Share---0.427-0.536+26%-0.545+28%-0.471+10%-0.330-23%
Usd Free Cash Flow To Equity Per Share---0.443-0.208-53%0.250-277%0.033-1443%0.058-863%
Usd Market Cap342870640.000-167%916058640.0002026480120.000-55%2052534120.000-55%2131165092.000-57%2368543086.000-61%
Usd Price Per Share3.290-167%8.79019.445-55%19.695-55%20.450-57%22.727-61%
Usd Profit---55699000.000-82561000.000+48%-88781750.000+59%-70409950.000+26%-47425400.000-15%
Usd Revenue--69799000.00058510000.000+19%33141250.000+111%23007050.000+203%11627850.000+500%
Usd Total Gains Per Share---0.436-0.373-14%-0.125-71%-0.137-69%0.004-10015%
 EOD+2 -6MRQTTM+14 -21YOY+15 -205Y+14 -2110Y+9 -26

4.2. Fundamental Score

Let's check the fundamental score of Revance The based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.539
Price to Book Ratio (EOD)Between0-1-2.262
Net Profit Margin (MRQ)Greater than0-0.798
Operating Margin (MRQ)Greater than0-0.761
Quick Ratio (MRQ)Greater than14.469
Current Ratio (MRQ)Greater than13.798
Debt to Asset Ratio (MRQ)Less than11.317
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.116
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Revance The based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.698
Ma 20Greater thanMa 504.146
Ma 50Greater thanMa 1005.043
Ma 100Greater thanMa 2005.981
OpenGreater thanClose3.500
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -374249-12564-6148-132714



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets478,454
Total Liabilities630,058
Total Stockholder Equity-151,604
 As reported
Total Liabilities 630,058
Total Stockholder Equity+ -151,604
Total Assets = 478,454

Assets

Total Assets478,454
Total Current Assets338,865
Long-term Assets139,589
Total Current Assets
Cash And Cash Equivalents 137,879
Short-term Investments 116,586
Net Receivables 27,676
Inventory 45,579
Other Current Assets 11,145
Total Current Assets  (as reported)338,865
Total Current Assets  (calculated)338,865
+/-0
Long-term Assets
Property Plant Equipment 90,207
Intangible Assets 9,808
Long-term Assets Other 32,704
Long-term Assets  (as reported)139,589
Long-term Assets  (calculated)132,719
+/- 6,870

Liabilities & Shareholders' Equity

Total Current Liabilities89,224
Long-term Liabilities540,834
Total Stockholder Equity-151,604
Total Current Liabilities
Short-term Debt 10,854
Short Long Term Debt 2,500
Accounts payable 13,809
Other Current Liabilities 53,824
Total Current Liabilities  (as reported)89,224
Total Current Liabilities  (calculated)80,987
+/- 8,237
Long-term Liabilities
Long term Debt 426,595
Capital Lease Obligations 49,339
Long-term Liabilities Other 2,835
Long-term Liabilities  (as reported)540,834
Long-term Liabilities  (calculated)478,769
+/- 62,065
Total Stockholder Equity
Common Stock88
Retained Earnings -2,078,360
Accumulated Other Comprehensive Income 14
Other Stockholders Equity 1,926,654
Total Stockholder Equity (as reported)-151,604
Total Stockholder Equity (calculated)-151,604
+/-0
Other
Capital Stock88
Cash and Short Term Investments 254,465
Common Stock Shares Outstanding 90,146
Current Deferred Revenue10,737
Liabilities and Stockholders Equity 478,454
Net Debt 340,555
Net Invested Capital 277,491
Net Working Capital 249,641
Property Plant and Equipment Gross 90,207
Short Long Term Debt Total 478,434



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-31
> Total Assets 
39,928
13,423
0
0
18,920
22,645
106,912
223,317
208,922
192,469
175,722
171,216
165,514
275,822
259,000
237,009
226,857
204,360
209,454
187,076
169,183
295,699
284,780
259,123
233,051
226,348
324,475
295,892
265,812
340,287
592,927
576,181
712,147
720,220
675,947
640,875
581,828
531,163
639,546
561,883
711,591
581,900
547,801
597,535
532,487
478,454
478,454532,487597,535547,801581,900711,591561,883639,546531,163581,828640,875675,947720,220712,147576,181592,927340,287265,812295,892324,475226,348233,051259,123284,780295,699169,183187,076209,454204,360226,857237,009259,000275,822165,514171,216175,722192,469208,922223,317106,91222,64518,9200013,42339,928
   > Total Current Assets 
0
5,405
0
0
3,030
4,814
91,172
206,558
190,910
172,731
155,689
137,256
143,497
253,963
238,490
218,557
208,679
192,695
197,453
174,353
156,267
285,211
273,418
242,882
215,884
207,922
277,116
249,905
220,568
296,602
518,441
502,771
450,105
450,003
406,427
354,604
293,883
246,117
285,330
260,945
415,594
374,727
323,024
378,947
388,519
338,865
338,865388,519378,947323,024374,727415,594260,945285,330246,117293,883354,604406,427450,003450,105502,771518,441296,602220,568249,905277,116207,922215,884242,882273,418285,211156,267174,353197,453192,695208,679218,557238,490253,963143,497137,256155,689172,731190,910206,55891,1724,8143,030005,4050
       Cash And Cash Equivalents 
29,621
4,083
0
0
1,909
3,914
87,853
203,308
187,486
171,032
153,717
96,417
90,494
201,615
40,793
52,651
130,481
63,502
38,235
53,693
56,323
282,896
69,212
39,282
45,132
73,256
65,269
90,034
58,922
171,160
286,649
363,511
339,439
333,558
249,427
167,634
127,177
110,623
198,359
69,418
104,491
108,965
136,678
141,235
179,319
137,879
137,879179,319141,235136,678108,965104,49169,418198,359110,623127,177167,634249,427333,558339,439363,511286,649171,16058,92290,03465,26973,25645,13239,28269,212282,89656,32353,69338,23563,502130,48152,65140,793201,61590,49496,417153,717171,032187,486203,30887,8533,9141,909004,08329,621
       Short-term Investments 
75
75
0
0
75
75
75
75
75
75
35
38,884
51,364
50,688
195,815
164,293
70,770
122,026
150,404
111,852
97,117
0
199,594
194,452
163,260
102,556
205,719
151,858
150,110
118,955
224,621
130,532
96,392
102,947
137,386
168,662
146,504
114,448
64,231
164,397
274,136
231,742
137,271
178,488
120,926
116,586
116,586120,926178,488137,271231,742274,136164,39764,231114,448146,504168,662137,386102,94796,392130,532224,621118,955150,110151,858205,719102,556163,260194,452199,594097,117111,852150,404122,02670,770164,293195,81550,68851,36438,88435757575757575007575
       Net Receivables 
0
0
0
0
0
225
1,786
188
1,421
300
300
0
0
158
158
0
0
6,026
0
0
0
48
48
0
0
27,000
0
0
5,000
0
0
49
2,585
1,829
5,186
641
1,658
3,348
4,471
5,590
11,732
11,339
15,373
17,043
25,414
27,676
27,67625,41417,04315,37311,33911,7325,5904,4713,3481,6586415,1861,8292,58549005,0000027,0000048480006,02600158158003003001,4211881,78622500000
       Inventory 
0
0
0
0
0
606
1,507
1,819
1,767
1,160
0
0
0
1,235
0
0
0
978
0
0
0
0
0
0
0
0
0
0
0
0
0
778
3,976
5,876
5,629
5,065
10,192
10,154
10,657
13,600
17,178
18,325
27,775
34,448
46,214
45,579
45,57946,21434,44827,77518,32517,17813,60010,65710,15410,1925,0655,6295,8763,97677800000000000009780001,2350001,1601,7671,8191,50760600000
   > Long-term Assets 
0
8,018
0
0
15,890
17,831
15,740
16,759
18,012
19,738
20,033
33,960
22,017
21,859
20,510
18,452
18,178
11,665
12,001
12,723
12,916
10,488
11,362
16,241
17,167
18,426
47,359
45,987
45,244
43,685
74,486
73,410
262,042
270,217
269,520
286,271
287,945
285,046
354,216
300,938
295,997
207,173
224,777
218,588
143,968
139,589
139,589143,968218,588224,777207,173295,997300,938354,216285,046287,945286,271269,520270,217262,04273,41074,48643,68545,24445,98747,35918,42617,16716,24111,36210,48812,91612,72312,00111,66518,17818,45220,51021,85922,01733,96020,03319,73818,01216,75915,74017,83115,890008,0180
       Property Plant Equipment 
8,439
6,980
0
0
13,054
14,315
15,150
16,324
17,394
19,274
19,390
19,134
19,254
19,708
19,714
17,658
17,385
10,585
11,205
11,255
11,500
9,250
10,064
12,196
13,493
14,449
43,483
42,865
41,995
41,286
39,928
39,061
40,289
47,131
49,545
67,426
67,562
69,001
136,828
81,795
73,220
67,755
79,662
73,588
95,198
90,207
90,20795,19873,58879,66267,75573,22081,795136,82869,00167,56267,42649,54547,13140,28939,06139,92841,28641,99542,86543,48314,44913,49312,19610,0649,25011,50011,25511,20510,58517,38517,65819,71419,70819,25419,13419,39019,27417,39416,32415,15014,31513,054006,9808,439
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
144,505
146,964
146,964
146,964
146,964
146,964
146,964
146,964
146,964
77,175
77,175
77,175
0
0
0077,17577,17577,175146,964146,964146,964146,964146,964146,964146,964146,964144,50500000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
14,052
2,357
1,751
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000001,7512,35714,05200000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,334
31,660
74,849
71,343
67,837
63,655
59,491
55,334
51,178
47,022
42,866
27,004
31,223
28,461
10,507
9,808
9,80810,50728,46131,22327,00442,86647,02251,17855,33459,49163,65567,83771,34374,84931,66032,334000000000000000000000000000000
       Long-term Assets Other 
0
1,038
0
0
2,836
3,516
590
435
618
464
643
774
406
400
796
794
793
1,080
796
1,468
1,416
1,238
1,298
4,045
3,674
3,977
3,876
3,122
3,249
2,399
2,224
2,689
2,399
4,779
5,174
8,226
13,928
13,747
19,246
25,157
32,947
35,239
36,717
39,364
38,263
32,704
32,70438,26339,36436,71735,23932,94725,15719,24613,74713,9288,2265,1744,7792,3992,6892,2242,3993,2493,1223,8763,9773,6744,0451,2981,2381,4161,4687961,0807937947964004067746434646184355903,5162,836001,0380
> Total Liabilities 
99,977
230,150
0
0
41,162
180,194
28,225
24,809
21,008
16,100
12,264
22,375
23,158
22,570
22,148
21,233
26,142
27,289
30,783
27,662
27,127
26,854
48,139
49,268
50,953
80,726
103,372
107,350
114,531
114,797
284,552
320,463
339,294
345,930
431,700
454,640
461,666
462,692
614,005
564,514
565,878
569,300
574,474
570,749
638,688
630,058
630,058638,688570,749574,474569,300565,878564,514614,005462,692461,666454,640431,700345,930339,294320,463284,552114,797114,531107,350103,37280,72650,95349,26848,13926,85427,12727,66230,78327,28926,14221,23322,14822,57023,15822,37512,26416,10021,00824,80928,225180,19441,16200230,15099,977
   > Total Current Liabilities 
8,855
117,935
0
0
31,675
47,561
22,609
18,765
14,747
10,236
6,427
10,157
11,739
12,037
12,488
11,918
17,516
19,647
24,042
21,976
21,476
20,902
22,996
28,324
31,808
31,970
34,070
44,696
34,154
40,979
41,635
47,993
63,653
60,964
50,838
58,248
65,874
67,289
71,066
77,226
74,732
75,682
77,985
74,079
82,158
89,224
89,22482,15874,07977,98575,68274,73277,22671,06667,28965,87458,24850,83860,96463,65347,99341,63540,97934,15444,69634,07031,97031,80828,32422,99620,90221,47621,97624,04219,64717,51611,91812,48812,03711,73910,1576,42710,23614,74718,76522,60947,56131,67500117,9358,855
       Short-term Debt 
0
95,449
0
0
8,270
22,864
13,405
11,045
8,764
2,942
319
2,906
3,018
3,135
3,256
3,314
3,339
3,475
3,502
3,550
2,727
1,872
983
0
0
14,407
3,009
3,168
3,317
3,470
3,627
3,789
4,040
4,437
4,472
5,646
4,829
4,746
23,687
22,695
13,500
4,912
23,088
20,766
18,519
10,854
10,85418,51920,76623,0884,91213,50022,69523,6874,7464,8295,6464,4724,4374,0403,7893,6273,4703,3173,1683,00914,407009831,8722,7273,5503,5023,4753,3393,3143,2563,1353,0182,9063192,9428,76411,04513,40522,8648,2700095,4490
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
2,942
0
0
0
3,135
0
0
0
3,475
4,485
3,550
2,727
1,872
983
0
0
0
3,009
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,250
2,500
2,5001,250000000000000000003,0090009831,8722,7273,5504,4853,4750003,1350002,942000000000
       Accounts payable 
777
1,805
0
0
10,054
5,526
3,689
2,687
2,666
3,149
2,089
2,211
2,731
2,657
3,307
2,982
2,871
3,754
5,573
4,079
6,680
6,805
5,361
5,435
7,341
8,434
4,486
7,966
6,902
8,010
8,709
6,603
7,860
12,657
7,079
8,176
8,038
10,603
10,020
13,272
744
4,546
12,996
8,345
4,775
13,809
13,8094,7758,34512,9964,54674413,27210,02010,6038,0388,1767,07912,6577,8606,6038,7098,0106,9027,9664,4868,4347,3415,4355,3616,8056,6804,0795,5733,7542,8712,9823,3072,6572,7312,2112,0893,1492,6662,6873,6895,52610,054001,805777
       Other Current Liabilities 
3,527
15,117
0
0
13,184
19,088
1,287
1,517
924
448
4,338
7,946
9,008
698
9,181
8,936
14,645
661
18,469
17,897
14,796
710
11,120
13,569
15,718
541
13,521
14,737
18,694
21,588
19,220
25,346
40,822
36,019
30,241
34,564
42,066
42,578
28,379
30,594
48,007
59,357
35,865
39,535
53,493
53,824
53,82453,49339,53535,86559,35748,00730,59428,37942,57842,06634,56430,24136,01940,82225,34619,22021,58818,69414,73713,52154115,71813,56911,12071014,79617,89718,46966114,6458,9369,1816989,0087,9464,3384489241,5171,28719,08813,1840015,1173,527
   > Long-term Liabilities 
0
112,215
0
0
9,487
132,633
5,616
6,044
6,261
5,864
5,837
12,218
11,419
10,533
9,660
9,315
8,626
7,642
6,741
5,686
5,651
5,952
25,143
20,944
19,145
48,756
69,302
62,654
80,377
73,818
242,917
272,470
275,641
284,966
380,862
396,392
395,792
395,403
542,939
487,288
491,146
493,618
496,489
496,670
556,530
540,834
540,834556,530496,670496,489493,618491,146487,288542,939395,403395,792396,392380,862284,966275,641272,470242,91773,81880,37762,65469,30248,75619,14520,94425,1435,9525,6515,6866,7417,6428,6269,3159,66010,53311,41912,2185,8375,8646,2616,0445,616132,6339,48700112,2150
       Long term Debt Total 
0
0
0
0
0
0
400
703
938
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
171,305
174,304
177,377
180,526
279,694
280,003
280,319
280,635
0
0
0
0
379,859
380,348
0
0
00380,348379,8590000280,635280,319280,003279,694180,526177,377174,304171,305000000000000000000000938703400000000
       Capital Lease Obligations Min Short Term Debt
0
-95,449
0
0
-8,270
-22,864
-13,405
-11,045
-8,764
-2,942
-319
-2,906
-3,018
-3,135
-3,256
-3,314
-3,339
-3,475
-3,502
-3,550
-2,727
-1,872
-983
0
0
-14,407
28,517
27,661
26,778
25,870
24,890
23,871
23,453
27,146
26,201
41,276
40,466
39,131
90,834
36,613
35,518
34,182
32,771
31,274
41,029
38,485
38,48541,02931,27432,77134,18235,51836,61390,83439,13140,46641,27626,20127,14623,45323,87124,89025,87026,77827,66128,517-14,40700-983-1,872-2,727-3,550-3,502-3,475-3,339-3,314-3,256-3,135-3,018-2,906-319-2,942-8,764-11,045-13,405-22,864-8,27000-95,4490
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
598
513
6,973
6,176
5,346
4,486
3,759
2,936
1,972
1,083
0
0
0
0
0
13,009
42,684
66,457
59,830
77,485
73,818
71,612
98,166
98,264
104,440
101,168
116,389
115,473
1,485
2,504
2,687
1,485
1,485
116,630
116,322
2,835
2,835
2,8352,835116,322116,6301,4851,4852,6872,5041,485115,473116,389101,168104,44098,26498,16671,61273,81877,48559,83066,45742,68413,009000001,0831,9722,9363,7594,4865,3466,1766,973513598000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
5,216
5,341
5,323
5,266
5,324
5,245
5,243
5,187
5,174
5,556
5,690
5,670
5,658
5,686
5,651
5,952
25,143
20,944
6,136
6,072
2,845
2,824
2,892
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000002,8922,8242,8456,0726,13620,94425,1435,9525,6515,6865,6585,6705,6905,5565,1745,1875,2435,2455,3245,2665,3235,3415,216000000
> Total Stockholder Equity
0
-216,727
0
0
-22,242
-157,549
78,687
198,508
187,914
176,369
163,458
148,841
142,356
253,252
236,852
215,776
200,715
177,071
178,671
159,414
142,056
268,845
236,641
209,855
182,098
145,622
221,103
188,542
151,281
225,490
308,375
255,718
372,853
374,290
244,247
186,235
120,162
68,471
25,541
-2,631
145,713
12,600
-26,673
26,786
-106,201
-151,604
-151,604-106,20126,786-26,67312,600145,713-2,63125,54168,471120,162186,235244,247374,290372,853255,718308,375225,490151,281188,542221,103145,622182,098209,855236,641268,845142,056159,414178,671177,071200,715215,776236,852253,252142,356148,841163,458176,369187,914198,50878,687-157,549-22,24200-216,7270
   Common Stock
0
0
0
0
10
3,358
19
23
24
24
24
24
24
28
28
28
29
29
30
30
31
37
37
37
37
37
44
44
44
52
57
57
67
69
71
72
72
72
72
73
82
82
84
88
88
88
888888848282737272727271696757575244444437373737373130302929282828242424242423193,358100000
   Retained Earnings Total Equity00-1,881,485-1,814,1670-1,608,422-1,523,729-1,462,294-1,397,952-1,334,854-1,260,478-1,188,281-1,126,293-1,047,984-966,727-906,137-844,204-798,878-757,469-720,079-684,775-644,158-611,284-577,204-542,167-506,261-475,610-448,736-421,500-394,741-376,762-352,161-332,300-310,179-291,004-274,199-258,797-244,585-230,608-217,306000000
   Accumulated Other Comprehensive Income 
0
-6,355
0
0
-7,739
-8,189
-8,675
-9,207
-9,749
-9,906
-9,906
-12
10
-40
186
148
16
-45
-98
-114
-43
-13,531
-276
-224
-133
-8
70
116
42
3
524
117
0
0
0
-2
-3
-18
-59
-386
-460
-374
-125
-61
-13
14
14-13-61-125-374-460-386-59-18-3-200011752434211670-8-133-224-276-13,531-43-114-98-4516148186-4010-12-9,906-9,906-9,749-9,207-8,675-8,189-7,73900-6,3550
   Capital Surplus 
0
0
0
0
0
0
295,974
429,093
432,475
435,142
437,633
439,833
452,501
585,537
588,799
592,362
595,411
598,630
627,475
635,108
648,329
810,975
814,084
821,326
826,352
830,368
941,068
945,851
950,073
1,069,639
1,213,931
1,222,271
1,420,770
1,500,514
1,432,457
1,446,643
1,454,947
1,466,369
1,487,822
1,521,411
1,754,513
0
1,787,535
1,908,244
0
0
001,908,2441,787,53501,754,5131,521,4111,487,8221,466,3691,454,9471,446,6431,432,4571,500,5141,420,7701,222,2711,213,9311,069,639950,073945,851941,068830,368826,352821,326814,084810,975648,329635,108627,475598,630595,411592,362588,799585,537452,501439,833437,633435,142432,475429,093295,974000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
7,954
0
0
171,288
46,520
197,737
214,983
233,302
445,048
437,633
439,821
452,511
596,969
588,985
592,510
595,427
610,743
627,377
634,994
648,286
824,506
813,808
821,102
826,219
844,332
941,138
945,967
950,115
1,086,508
1,213,455
1,222,388
1,420,770
1,500,514
1,432,457
1,446,643
1,454,947
1,466,369
1,487,822
1,521,411
1,754,513
1,767,266
1,787,535
1,908,244
1,916,385
1,926,654
1,926,6541,916,3851,908,2441,787,5351,767,2661,754,5131,521,4111,487,8221,466,3691,454,9471,446,6431,432,4571,500,5141,420,7701,222,3881,213,4551,086,508950,115945,967941,138844,332826,219821,102813,808824,506648,286634,994627,377610,743595,427592,510588,985596,969452,511439,821437,633445,048233,302214,983197,73746,520171,288007,9540



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue234,040
Cost of Revenue-88,056
Gross Profit145,984145,984
 
Operating Income (+$)
Gross Profit145,984
Operating Expense-366,709
Operating Income-220,725-220,725
 
Operating Expense (+$)
Research Development74,471
Selling General Administrative38,814
Selling And Marketing Expenses253,424
Operating Expense366,709366,709
 
Net Interest Income (+$)
Interest Income12,882
Interest Expense-19,356
Other Finance Cost-1,646
Net Interest Income-4,828
 
Pretax Income (+$)
Operating Income-220,725
Net Interest Income-4,828
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-323,686-117,764
EBIT - interestExpense = -240,081
-323,686
-304,630
Interest Expense19,356
Earnings Before Interest and Taxes (EBIT)-220,725-304,330
Earnings Before Interest and Taxes (EBITDA)-207,032
 
After tax Income (+$)
Income Before Tax-323,686
Tax Provision-300
Net Income From Continuing Ops-414,239-323,986
Net Income-323,986
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses454,765
Total Other Income/Expenses Net-102,9614,828
 

Technical Analysis of Revance
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Revance. The general trend of Revance is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Revance's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Revance The.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.94 < 5.2 < 7.56.

The bearish price targets are: .

Tweet this
Revance The Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Revance The. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Revance The Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Revance The. The current macd is -0.45309339.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Revance price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Revance. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Revance price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Revance The Daily Moving Average Convergence/Divergence (MACD) ChartRevance The Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Revance The. The current adx is 27.89.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Revance shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Revance The Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Revance The. The current sar is 4.07064755.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Revance The Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Revance The. The current rsi is 23.70. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Revance The Daily Relative Strength Index (RSI) ChartRevance The Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Revance The. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Revance price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Revance The Daily Stochastic Oscillator ChartRevance The Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Revance The. The current cci is -139.54181045.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Revance The Daily Commodity Channel Index (CCI) ChartRevance The Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Revance The. The current cmo is -67.88209819.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Revance The Daily Chande Momentum Oscillator (CMO) ChartRevance The Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Revance The. The current willr is -96.49122807.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Revance The Daily Williams %R ChartRevance The Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Revance The.

Revance The Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Revance The. The current atr is 0.29507447.

Revance The Daily Average True Range (ATR) ChartRevance The Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Revance The. The current obv is -106,350,788.

Revance The Daily On-Balance Volume (OBV) ChartRevance The Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Revance The. The current mfi is 18.53.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Revance The Daily Money Flow Index (MFI) ChartRevance The Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Revance The.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Revance The Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Revance The based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.698
Ma 20Greater thanMa 504.146
Ma 50Greater thanMa 1005.043
Ma 100Greater thanMa 2005.981
OpenGreater thanClose3.500
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Revance with someone you think should read this too:
  • Are you bullish or bearish on Revance? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Revance? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Revance The

I send you an email if I find something interesting about Revance The.


Comments

How you think about this?

Leave a comment

Stay informed about Revance The.

Receive notifications about Revance The in your mailbox!